

**WHAT IS CLAIMED IS:**

1. A pharmaceutical composition, comprising (i) formoterol, or a derivative thereof; and (ii) a steroid anti-inflammatory agent, or a derivative thereof;
- 5 in a pharmacologically suitable fluid, wherein the composition is stable during long term storage and the fluid comprises water.
2. The pharmaceutical composition of claim 1, wherein the composition has an estimated shelf-life of greater than 1 month usage time at 25 °C and greater than or equal to 1 year storage time at 5 °C.
- 10 3. The pharmaceutical composition of claim 2, wherein greater than about 80% of the initial formoterol is present after 1 month usage time at 25 °C and 1 year storage time at 5 °C.
4. The pharmaceutical composition of claim 1 that has been nebulized.
- 15 5. The pharmaceutical composition of claim 1, wherein the pharmacologically suitable fluid comprises a polar solvent.
6. The pharmaceutical composition of claim 5, wherein the polar solvent is a protic solvent.
7. The pharmaceutical composition of claim 6, further
- 20 comprising a tonicity adjusting agent.
8. The pharmaceutical composition of claim 7, wherein the tonicity adjusting agent is ammonium carbonate, ammonium chloride, ammonium lactate, ammonium nitrate, ammonium phosphate, ammonium sulfate, ascorbic acid, bismuth sodium tartrate, boric acid, calcium
- 25 chloride, calcium disodium edetate, calcium gluconate, calcium lactate, citric acid, dextrose, diethanolamine, dimethylsulfoxide, edetate disodium, edetate trisodium monohydrate, fluorescein sodium, fructose, galactose, glycerin, lactic acid, lactose, magnesium chloride, magnesium sulfate, mannitol, polyethylene glycol, potassium acetate, potassium chlorate,
- 30 potassium chloride, potassium iodide, potassium nitrate, potassium phosphate, potassium sulfate, propylene glycol, silver nitrate, sodium

acetate, sodium bicarbonate, sodium biphosphate, sodium bisulfite, sodium borate, sodium bromide, sodium cacodylate, sodium carbonate, sodium chloride, sodium citrate, sodium iodide, sodium lactate, sodium metabisulfite, sodium nitrate, sodium nitrite, sodium phosphate, sodium 5 propionate, sodium succinate, sodium sulfate, sodium sulfite, sodium tartrate, sodium thiosulfate, sorbitol, sucrose, tartaric acid, triethanolamine, urea, urethan, uridine or zinc sulfate.

9. The pharmaceutical composition of claim 8, wherein the tonicity adjusting agent is sodium chloride.

10 10. The pharmaceutical composition of claim 1, wherein the pharmacologically suitable fluid comprises a buffer.

11. The pharmaceutical composition of claim 10, wherein the buffer is citric acid/phosphate, acetate, barbital, borate, Britton-Robinson, cacodylate, citrate, collidine, formate, maleate, McIlvaine, phosphate, 15 Prideaux-Ward, succinate, citrate-phosphate-borate (Teorell-Stanhagen), veronal acetate, MES (2-(N-morpholino)ethanesulfonic acid), BIS-TRIS (bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane), ADA (N-(2-acetamido)-2-iminodiacetic acid), ACES (N-(carbamoylmethyl)-2-aminoethanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MOPSO (3-(N-morpholino)-2-hydroxypropanesulfonic acid), BIS-TRIS PROPANE (1,3-bis(tris(hydroxymethyl)methylamino)propane), BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), TES (N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid), HEPES (N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)), DIPSO (3-(N,N-bis(2-hydroxyethyl)amino)-2-hydroxypropanesulfonic acid), MOBS (4-(N-morpholino)butanesulfonic acid), TAPSO (3-(N-tris(hydroxymethyl)methylamino)-2-hydroxypropanesulfonic acid), tris(hydroxymethylaminomethane, HEPPSO (N-(2-hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)), POPSO 25 (piperazine-N,N'-bis(2-hydroxypropanesulfonic acid)), TEA (triethanolamine), EPPS (N-(2-hydroxyethyl)piperazine-N'-(3-propane-

sulfonic acid), TRICINE (N-tris(hydroxymethyl)methylglycine), GLY-GLY (glycylglycine), BICINE (N,N-bis(2-hydroxyethyl)glycine), HEPBS (N-(2-hydroxyethyl)piperazine-N'-(4-butanesulfonic acid)), TAPS (N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid), or AMPD (2-amino-2-

5 methyl-1,3-propanediol) buffer.

12. The pharmaceutical composition of claim 11, wherein the buffer is citrate buffer.

13. The pharmaceutical composition of claim 12, wherein the buffer concentration is from about 0.01 mM to about 150 mM.

10 14. The pharmaceutical composition of claim 13, wherein the buffer concentration is from about 1 mM to about 20 mM.

15. The pharmaceutical composition of claim 14, wherein the buffer concentration is about 5 mM.

16. The pharmaceutical composition of claim 8, wherein the 15 ionic strength of the composition is about 0 to about 0.4.

17. The pharmaceutical composition of claim 16, wherein the ionic strength of the composition is about 0.05 to about 0.16.

18. The pharmaceutical composition of claim 1, wherein the pH of the composition is about 2.0 to about 8.0.

20 19. The pharmaceutical composition of claim 18, wherein the pH of the composition is about 4.0 to about 6.0.

20. The pharmaceutical composition of claim 19, wherein the pH of the composition is about 4.5 to about 5.5.

25 21. The pharmaceutical composition of claim 20, wherein the pH of the composition is about 5.0.

22. The pharmaceutical composition of claim 1, wherein the formoterol free base concentration is about 5  $\mu$ g/mL to about 2 mg/mL.

23. The pharmaceutical composition of claim 22, wherein the formoterol free base concentration is about 10  $\mu$ g/mL to about 1 mg/mL.

24. The pharmaceutical composition of claim 23, wherein the formoterol free base concentration is about 50  $\mu\text{g}/\text{mL}$  to about 200  $\mu\text{g}/\text{mL}$ .
25. The pharmaceutical composition of claim 24, wherein the 5 formoterol free base concentration is about 59  $\mu\text{g}/\text{mL}$ .
26. The pharmaceutical composition of claim 24, wherein the formoterol free base concentration is about 118  $\mu\text{g}/\text{mL}$ .
27. The pharmaceutical composition of claim 8, further comprising a buffer.
- 10 28. The pharmaceutical composition of claim 27, wherein the buffer is citric acid/phosphate, acetate, barbital, borate, Britton-Robinson, cacodylate, citrate, collidine, formate, maleate, McIlvaine, phosphate, Prideaux-Ward, succinate, citrate-phosphate-borate (Teorell-Stanhagen), veronal acetate, MES (2-(N-morpholino)ethanesulfonic acid), BIS-TRIS
- 15 (bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane), ADA (N-(2-acetamido)-2-iminodiacetic acid), ACES (N-(carbamoylmethyl)-2-aminoethanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MOPSO (3-(N-morpholino)-2-hydroxypropanesulfonic acid), BIS-TRIS PROPANE (1,3-bis(tris(hydroxymethyl)methylamino)propane), BES
- 20 (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), TES (N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid), HEPES (N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)), DIPSO (3-(N,N-bis(2-hydroxyethyl)amino)-2-hydroxypropanesulfonic acid), MOBS (4-(N-morpholino)butanesulfonic acid), TAPSO (3-(N-tris(hydroxymethyl)methylamino)-2-hydroxypropanesulfonic acid), tris(hydroxymethylaminomethane), HEPPSO (N-(2-hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)), POPSO (piperazine-N,N'-bis(2-hydroxypropanesulfonic acid)), TEA (triethanolamine), EPPS (N-(2-hydroxyethyl)piperazine-N'-(3-propanesulfonic acid)), TRICINE (N-tris(hydroxymethyl)methylglycine), GLY-GLY (glycylglycine), BICINE (N,N-bis(2-hydroxyethyl)glycine), HEPBS (N-(2-
- 25
- 30

hydroxyethyl)piperazine-N'-(4-butanesulfonic acid)), TAPS (N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid), or AMPD (2-amino-2-methyl-1,3-propanediol) buffer.

29. The pharmaceutical composition of claim 28, wherein the  
5 buffer is citrate buffer.

30. The pharmaceutical composition of claim 29, wherein the buffer concentration is from about 0.01 mM to about 150 mM.

31. The pharmaceutical composition of claim 30, wherein the buffer concentration is from about 1 mM to about 20 mM.

10 32. The pharmaceutical composition of claim 31, wherein the buffer concentration is about 5 mM.

33. The pharmaceutical composition of claim 27, wherein the ionic strength of the composition is about 0 to about 0.4.

15 34. The pharmaceutical composition of claim 33, wherein the ionic strength of the composition is about 0.05 to about 0.16.

35. The pharmaceutical composition of claim 27, wherein the pH of the composition is about 2.0 to about 8.0.

36. The pharmaceutical composition of claim 35, wherein the pH of the composition is about 4.0 to about 6.0.

20 37. The pharmaceutical composition of claim 36, wherein the pH of the composition is about 4.5 to about 5.5.

38. The pharmaceutical composition of claim 37, wherein the pH of the composition is about 5.0.

25 39. The pharmaceutical composition of claim 27, wherein the formoterol free base concentration is about 5  $\mu$ g/mL to about 2 mg/mL.

40. The pharmaceutical composition of claim 39, wherein the formoterol free base concentration is about 10  $\mu$ g/mL to about 1 mg/mL.

41. The pharmaceutical composition of claim 40, wherein the formoterol free base concentration is about 50  $\mu$ g/mL to about 200  
30  $\mu$ g/mL.

42. The pharmaceutical composition of claim 41, wherein the formoterol free base concentration is about 59  $\mu\text{g}/\text{mL}$ .
43. The pharmaceutical composition of claim 41, wherein the formoterol free base concentration is about 118  $\mu\text{g}/\text{mL}$ .
- 5        44. The pharmaceutical composition of claim 25 that has been nebulized.
45. The pharmaceutical composition of claim 26 that has been nebulized.
- 10      46. The pharmaceutical composition of claim 42 that has been nebulized.
47. The pharmaceutical composition of claim 43 that has been nebulized.
48. The pharmaceutical composition of claim 27 that has been nebulized.
- 15      49. The pharmaceutical composition of claim 42, wherein the buffer is citrate buffer.
50. The pharmaceutical composition of claim 42, wherein the buffer concentration is about 5 mM.
- 20      51. The pharmaceutical composition of claim 42, wherein the ionic strength of the composition is about 0.05 to about 0.16.
52. The pharmaceutical composition of claim 42, wherein the pH of the composition is about 5.0.
- 25      53. The pharmaceutical composition of claim 42, wherein the buffer is citrate buffer; the buffer concentration is about 5 mM; the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
54. The pharmaceutical composition of claim 43, wherein the buffer is citrate buffer.
- 30      55. The pharmaceutical composition of claim 43, wherein the buffer concentration is about 5 mM.

56. The pharmaceutical composition of claim 43, wherein the ionic strength of the composition is about 0.05 to about 0.16.
57. The pharmaceutical composition of claim 43, wherein the pH of the composition is about 5.0.
- 5 58. The pharmaceutical composition of claim 43, wherein the buffer is citrate buffer; the buffer concentration is about 5 mM; the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
- 10 59. The pharmaceutical composition of claim 53 that has been nebulized.
60. The pharmaceutical composition of claim 58 that has been nebulized.
- 15 61. The pharmaceutical composition of claim 11, wherein the buffer comprises citric acid/phosphate buffer, acetate buffer, citrate buffer or phosphate buffer.
62. The pharmaceutical composition of claim 27, wherein the buffer comprises citric acid/phosphate buffer, acetate buffer, citrate buffer or phosphate buffer.
- 20 63. The pharmaceutical composition of claim 1, wherein the steroid anti-inflammatory agent is beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, rofleponide, mometasone, mometasone furoate, RPR 106541, fluticasone or fluticasone propionate or budesonide, or a derivative thereof.
- 25 64. The pharmaceutical composition of claim 63, wherein the steroid anti-inflammatory agent is budesonide or fluticasone propionate, or a derivative thereof.
65. The pharmaceutical composition of claim 64, wherein the steroid anti-inflammatory agent is budesonide, or a derivative thereof.
- 30 66. The pharmaceutical composition of claim 65, wherein the budesonide concentration is about 5 µg/mL to about 2 mg/mL.

67. The pharmaceutical composition of claim 65, wherein the budesonide concentration is about 75  $\mu\text{g}/\text{mL}$  to about 500  $\mu\text{g}/\text{mL}$ .

68. The pharmaceutical composition of claim 65, wherein the budesonide concentration is about 125  $\mu\text{g}/\text{mL}$  or about 250  $\mu\text{g}/\text{mL}$ .

5 69. The pharmaceutical composition of claim 64, wherein the steroid anti-inflammatory agent is fluticasone propionate.

70. The pharmaceutical composition of claim 69, wherein the concentration of fluticasone propionate is about 5  $\mu\text{g}/\text{mL}$  to about 2 mg/mL.

10 71. The pharmaceutical composition of claim 70, wherein the concentration of fluticasone propionate is about 75  $\mu\text{g}/\text{mL}$  to about 1000  $\mu\text{g}/\text{mL}$ .

15 72. The pharmaceutical composition of claim 71, wherein the concentration of fluticasone propionate is about 125  $\mu\text{g}/\text{mL}$  or about 250  $\mu\text{g}/\text{mL}$ .

73. The pharmaceutical composition of claim 53, wherein the steroid anti-inflammatory agent is budesonide or fluticasone propionate.

74. The pharmaceutical composition of claim 58, wherein the steroid anti-inflammatory agent is budesonide or fluticasone propionate.

20 75. The pharmaceutical composition of claim 1 that is a solution.

76. The pharmaceutical composition of claim 1 that is a suspension.

25 77. A nebulized suspension or solution, comprising (i) formoterol or a derivative thereof; and (ii) a steroid anti-inflammatory agent, or a derivative thereof; in a pharmacologically suitable fluid.

78. A kit, comprising:

- (a) an aqueous composition comprising (i) formoterol or a derivative thereof, and (ii) a steroid anti-inflammatory agent or a derivative thereof, formulated for single dosage administration; and
- (b) a nebulizer.

79. The kit of claim 78, wherein the aqueous composition comprises (a) formoterol free base at a concentration of about 59  $\mu\text{g}/\text{mL}$ ; (b) aqueous saline comprising sodium chloride; and (c) citrate buffer at a concentration of about 5 mM;
- 5       wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
80. The kit of claim 78, wherein the aqueous composition comprises (a) formoterol free base at a concentration of about 118  $\mu\text{g}/\text{mL}$ ; (b) aqueous saline comprising sodium chloride; and (c) citrate
- 10     buffer at a concentration of about 5 mM;
- wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
81. A combination, comprising:
- 15     (a) the pharmaceutical composition of claim 1 formulated for single dosage administration; and
- (b) a vial.
82. The combination of claim 81, wherein the aqueous composition comprises (a) formoterol free base at a concentration of about 59  $\mu\text{g}/\text{mL}$ ; (b) aqueous saline comprising sodium chloride; and (c)
- 20     citrate buffer at a concentration of about 5 mM;
- wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
83. The combination of claim 81, wherein the aqueous composition comprises (a) formoterol free base at a concentration of
- 25     about 118  $\mu\text{g}/\text{mL}$ ; (b) aqueous saline comprising sodium chloride; and (c) citrate buffer at a concentration of about 5 mM;
- wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
84. A method for the treatment, prevention, or amelioration of
- 30     one or more symptoms of bronchoconstrictive disorders, comprising

18025-1014  
20200915-A001

administering an effective amount of the pharmaceutical composition of claim 1 to a subject in need of such treatment.

85. A method for the treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders, comprising
- 5 administering an effective amount of the pharmaceutical composition of claim 73 to a subject in need of such treatment.

86. A method for the treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders, comprising
- administering an effective amount of the pharmaceutical composition of
- 10 claim 74 to a subject in need of such treatment.

87. An article of manufacture, comprising packaging material, an aqueous composition comprising the composition of claim 1 formulated for single dosage administration, which is useful for treatment, prevention or amelioration of one or more symptoms of diseases or disorders
- 15 associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the composition is used for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction.

88. An article of manufacture, comprising packaging material,
- 20 the composition of claim 73 formulated for single dosage administration, which is useful for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the composition is used for treatment, prevention or amelioration of one or
- 25 more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction.

89. An article of manufacture, comprising packaging material, the composition of claim 74 formulated for single dosage administration, which is useful for treatment, prevention or amelioration of one or more
- 30 symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the

composition is used for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction.

90. The method of claim 84, further comprising administering  
5 one or more of (a) to (j) as follows: (a) a  $\beta_2$ -adrenoreceptor agonist; (b) a dopamine (D<sub>2</sub>) receptor agonist; (c) an IL-5 inhibitor; (d) an antisense modulator of IL-5; (e) a tryptase inhibitor; (f) a tachykinin receptor antagonist; (g) milrinone or milrinone lactate; (h) a leukotriene receptor antagonist; (i) a 5-lipoxygenase inhibitor; or (j) an anti-IgE antibody;  
10 simultaneously with, prior to or subsequent to the formoterol/steroidal anti-inflammatory agent composition.

91. The method of claim 85, further comprising administering  
one or more of (a) to (j) as follows: (a) a  $\beta_2$ -adrenoreceptor agonist; (b) a dopamine (D<sub>2</sub>) receptor agonist; (c) an IL-5 inhibitor; (d) an antisense modulator of IL-5; (e) a tryptase inhibitor; (f) a tachykinin receptor antagonist; (g) milrinone or milrinone lactate; (h) a leukotriene receptor antagonist; (i) a 5-lipoxygenase inhibitor; or (j) an anti-IgE antibody;  
15 simultaneously with, prior to or subsequent to the formoterol/steroidal anti-inflammatory agent composition.

92. The method of claim 86, further comprising administering  
one or more of (a) to (j) as follows: (a) a  $\beta_2$ -adrenoreceptor agonist; (b) a dopamine (D<sub>2</sub>) receptor agonist; (c) an IL-5 inhibitor; (d) an antisense modulator of IL-5; (e) a tryptase inhibitor; (f) a tachykinin receptor antagonist; (g) milrinone or milrinone lactate; (h) a leukotriene receptor  
20 antagonist; (i) a 5-lipoxygenase inhibitor; or (j) an anti-IgE antibody;  
25 simultaneously with, prior to or subsequent to the formoterol/steroidal anti-inflammatory agent composition.

93. The pharmaceutical composition of claim 1, further  
comprising one or more of (a) to (j) as follows: (a) a  $\beta_2$ -adrenoreceptor  
30 agonist; (b) a dopamine (D<sub>2</sub>) receptor agonist; (c) an IL-5 inhibitor; (d) an antisense modulator of IL-5; (e) a tryptase inhibitor; (f) a tachykinin

receptor antagonist; (g) milrinone or milrinone lactate; (h) a leukotriene receptor antagonist; (i) a 5-lipoxygenase inhibitor; or (j) an anti-IgE antibody.

94. A method for the treatment, prevention, or amelioration of  
5 one or more symptoms of bronchoconstrictive disorders, comprising:  
    (i) administering an effective amount of a pharmaceutical composition comprising formoterol, or a derivative thereof, in a pharmacologically suitable fluid, wherein the composition is stable during long term storage and the fluid comprises water; and  
10     (ii) simultaneously with, prior to, or subsequent to administering the formoterol composition, administering an effective amount of a pharmaceutical composition comprising a steroidal anti-inflammatory agent in a pharmacologically acceptable carrier.

95. The method of claim 94, wherein the steroidal anti-inflammatory agent is beclomethasone dipropionate (BDP),  
15 beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, rofleponide, mometasone, mometasone furoate, RPR 106541, fluticasone or fluticasone propionate or budesonide, or a derivative thereof.

- 20 96. The method of claim 95, wherein the steroidal anti-inflammatory agent is fluticasone propionate or budesonide, or a derivative thereof.

97. The method of claim 95, wherein the steroidal anti-inflammatory agent is budesonide, or a derivative thereof.

- 25 98. The method of claim 95, wherein the steroidal anti-inflammatory agent is fluticasone propionate, or a derivative thereof.

99. The pharmaceutical composition of claim 13, wherein the buffer concentration is from about 1 mM to about 50 mM.

100. The pharmaceutical composition of claim 99, wherein the  
30 buffer concentration is about 20 mM.

101. The pharmaceutical composition of claim 30, wherein the buffer concentration is from about 1 mM to about 50 mM.
102. The pharmaceutical composition of claim 101, wherein the buffer concentration is about 20 mM.
- 5 103. The pharmaceutical composition of claim 42, wherein the buffer concentration is about 20 mM.
104. The pharmaceutical composition of claim 42, wherein the buffer is citrate buffer; the buffer concentration is about 20 mM; the ionic strength of the composition is about 0.05 to about 0.16; and the pH of  
10 the composition is about 5.0.
105. The pharmaceutical composition of claim 43, wherein the buffer concentration is about 20 mM.
106. The pharmaceutical composition of claim 43, wherein the buffer is citrate buffer; the buffer concentration is about 20 mM; the ionic  
15 strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
107. The pharmaceutical composition of claim 104 that has been nebulized.
108. The pharmaceutical composition of claim 106 that has been  
20 nebulized.
109. The kit of claim 78, wherein the aqueous composition comprises (a) formoterol free base at a concentration of about 59  $\mu$ g/mL; (b) aqueous saline comprising sodium chloride; and (c) citrate buffer at a concentration of about 20 mM;
- 25 wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.
110. The kit of claim 78, wherein the aqueous composition comprises (a) formoterol free base at a concentration of about 118  $\mu$ g/mL; (b) aqueous saline comprising sodium chloride; and (c) citrate  
30 buffer at a concentration of about 20 mM;

wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.

111. The combination of claim 81, wherein the aqueous composition comprises (a) formoterol free base at a concentration of 5 about 59  $\mu\text{g}/\text{mL}$ ; (b) aqueous saline comprising sodium chloride; and (c) citrate buffer at a concentration of about 20 mM;

wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.

112. The combination of claim 81, wherein the aqueous 10 composition comprises (a) formoterol free base at a concentration of about 118  $\mu\text{g}/\text{mL}$ ; (b) aqueous saline comprising sodium chloride; and (c) citrate buffer at a concentration of about 20 mM;
- wherein the ionic strength of the composition is about 0.05 to about 0.16; and the pH of the composition is about 5.0.

- 15 113. The pharmaceutical composition of claim 1, further comprising an anticholinergic agent.

114. The pharmaceutical composition of claim 113, wherein the anticholinergic agent is ipratropium bromide, oxitropium bromide, atropine methyl nitrate, tiotropium bromide or glycopyrronium bromide.

- 20 115. The pharmaceutical composition of claim 114, wherein the anticholinergic agent is ipratropium bromide.

116. The pharmaceutical composition of claim 115, wherein the ipratropium bromide is present at a concentration of about 5  $\mu\text{g}/\text{mL}$  to about 5 mg/mL.

- 25 117. A combination, comprising:
- a composition comprising formoterol, or a derivative thereof, in a pharmacologically suitable fluid, wherein the composition is stable during long term storage and the fluid comprises water; and
- a composition comprising a bronchodilating steroid, or a derivative 30 thereof.

118. The combination of claim 117, further comprising a nebulizer.

119. The combination of claim 118 that is packaged as a kit; optionally comprising instructions for use of the nebulizer; and optionally  
5 comprising instructions for mixing the compositions.

120. The pharmaceutical composition of claim 114, wherein the anticholinergic agent is tiotropium bromide.

121. The pharmaceutical composition of claim 115, wherein the tiotropium bromide is present at a concentration of about 5  $\mu\text{g}/\text{mL}$  to  
10 about 5 mg/mL.